AR062471A1 - SESQUIHIDRATO CRISTALINO DEL TARTRATO DE 1-[2-FLUORO-4-(TRIFLUOROMETIL)-3-(3-{[4-METIL-5-(4-METIL-1, 3-OXAZOL-5-IL)-4H-1, 2, 4-TRIAZOL-3-IL]TIO}PROPIL)-3-AZABICICLO[3.1.0]HEXANO (1S, 5R) o (2R, 3R), SU USO PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA MODU - Google Patents

SESQUIHIDRATO CRISTALINO DEL TARTRATO DE 1-[2-FLUORO-4-(TRIFLUOROMETIL)-3-(3-{[4-METIL-5-(4-METIL-1, 3-OXAZOL-5-IL)-4H-1, 2, 4-TRIAZOL-3-IL]TIO}PROPIL)-3-AZABICICLO[3.1.0]HEXANO (1S, 5R) o (2R, 3R), SU USO PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA MODU

Info

Publication number
AR062471A1
AR062471A1 ARP070103715A ARP070103715A AR062471A1 AR 062471 A1 AR062471 A1 AR 062471A1 AR P070103715 A ARP070103715 A AR P070103715A AR P070103715 A ARP070103715 A AR P070103715A AR 062471 A1 AR062471 A1 AR 062471A1
Authority
AR
Argentina
Prior art keywords
methyl
hexane
oxazol
triazol
tartrate
Prior art date
Application number
ARP070103715A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37081324&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR062471(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2006/008314 external-priority patent/WO2007022980A1/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AR062471A1 publication Critical patent/AR062471A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuesto de azabiciclo[3.1.0]-hexano que es el tartrato de 1-[2-fluoro-4-(trifluorometil)fenil]-3-(3-{[4-metil-5-(4-metil-1,3-oxazol-5-iI)-4H-1,2,4-triazol-3-il]tio}propil)-3-azabiciclo[3.1.0]-hexano o el derivado (1S,5R) o el derivado (2R,3R) o su solvato farmacéuticamente aceptable y sus formas cristalinas identificadas por sus espectros de calorimetría de barrido diferencial y diagramas de difraccion de rayos X. Su uso para la fabricacion de un medicamento util para el tratamiento de una afeccion en un mamífero para la cual la modulacion de los receptores de dopamina D3 es beneficiosa, como ser trastornos relacionados con sustancias. Composicion farmacéutica que lo comprende.
ARP070103715A 2006-08-21 2007-08-21 SESQUIHIDRATO CRISTALINO DEL TARTRATO DE 1-[2-FLUORO-4-(TRIFLUOROMETIL)-3-(3-{[4-METIL-5-(4-METIL-1, 3-OXAZOL-5-IL)-4H-1, 2, 4-TRIAZOL-3-IL]TIO}PROPIL)-3-AZABICICLO[3.1.0]HEXANO (1S, 5R) o (2R, 3R), SU USO PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA MODU AR062471A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0616574.0A GB0616574D0 (en) 2006-08-21 2006-08-21 Compounds
PCT/EP2006/008314 WO2007022980A1 (en) 2005-08-22 2006-08-21 Use of azabicyclo hexane derivatives

Publications (1)

Publication Number Publication Date
AR062471A1 true AR062471A1 (es) 2008-11-12

Family

ID=37081324

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103715A AR062471A1 (es) 2006-08-21 2007-08-21 SESQUIHIDRATO CRISTALINO DEL TARTRATO DE 1-[2-FLUORO-4-(TRIFLUOROMETIL)-3-(3-{[4-METIL-5-(4-METIL-1, 3-OXAZOL-5-IL)-4H-1, 2, 4-TRIAZOL-3-IL]TIO}PROPIL)-3-AZABICICLO[3.1.0]HEXANO (1S, 5R) o (2R, 3R), SU USO PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA MODU

Country Status (22)

Country Link
US (1) US20080058398A1 (es)
EP (1) EP2054054A1 (es)
JP (1) JP5315244B2 (es)
KR (1) KR101495362B1 (es)
CN (1) CN101528221B (es)
AR (1) AR062471A1 (es)
AU (1) AU2007287527B2 (es)
BR (1) BRPI0716454A2 (es)
CA (1) CA2661437A1 (es)
CL (1) CL2007002422A1 (es)
CO (1) CO6150139A2 (es)
CR (1) CR10638A (es)
EA (1) EA017917B1 (es)
GB (1) GB0616574D0 (es)
IL (1) IL196976A0 (es)
MA (1) MA30672B1 (es)
MX (1) MX2009001941A (es)
NO (1) NO20090834L (es)
PE (1) PE20080609A1 (es)
TW (1) TW200825074A (es)
WO (1) WO2008022994A1 (es)
ZA (1) ZA200900886B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7855298B2 (en) * 2004-02-23 2010-12-21 Glaxo Group Limited Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors
GB0507602D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507601D0 (en) * 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
DE602006017543D1 (de) * 2005-06-14 2010-11-25 Glaxo Group Ltd Neue verbindungen
GB0512099D0 (en) * 2005-06-14 2005-07-20 Glaxo Group Ltd Compounds
GB0517191D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
DE602006018152D1 (de) * 2005-08-22 2010-12-23 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3-rezeptoren
GB0517187D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517175D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use
EP2007751B1 (en) * 2006-04-03 2013-08-21 Glaxo Group Limited Azabicyclo [3. 1. o] hexyl derivatives as modulators of dopamine d3 receptors
EP2010518B1 (en) * 2006-04-03 2011-02-16 Glaxo Group Limited Azabicyclo [3. 1. o] hexane derivatives as modulators of dopamine d3 receptors
US9133159B2 (en) 2007-06-06 2015-09-15 Neurovance, Inc. 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
US20090069374A1 (en) * 2007-06-06 2009-03-12 Phil Skolnick Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes, Methods For Their Preparation And Their Use As Medicaments
JP7250405B2 (ja) 2018-01-26 2023-04-03 塩野義製薬株式会社 ドーパミンｄ３受容体拮抗作用を有する環式化合物
TWI822326B (zh) 2021-09-14 2023-11-11 美商美國禮來大藥廠 Sstr4促效劑鹽

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4260941B2 (ja) * 1998-11-09 2009-04-30 株式会社片山製薬所 アゼチジン−３−オール
EP1163217B1 (en) * 1999-03-15 2005-09-21 Novo Nordisk A/S New salt of (2r,3r,4r)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
GB0019228D0 (en) * 2000-08-04 2000-09-27 Smithkline Beecham Plc Novel pharmaceutical
US7855298B2 (en) * 2004-02-23 2010-12-21 Glaxo Group Limited Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors
SE526837C2 (sv) 2004-02-24 2005-11-08 Kongsberg Automotive Asa Växelspakstransmission
AU2005267579A1 (en) * 2004-06-30 2006-02-02 Eli Lilly And Company 1 (indole-6-carbonyl-D-phenylglycinyl) -4- (1-methylpiperidin-4-yl) piperazine D-tartrate
GB0517193D0 (en) * 2005-08-22 2005-09-28 Glaxo Group Ltd Novel use

Also Published As

Publication number Publication date
CN101528221B (zh) 2013-05-08
KR20090052327A (ko) 2009-05-25
CN101528221A (zh) 2009-09-09
PE20080609A1 (es) 2008-07-26
CA2661437A1 (en) 2008-02-28
CR10638A (es) 2009-03-20
CL2007002422A1 (es) 2008-03-14
EP2054054A1 (en) 2009-05-06
MX2009001941A (es) 2009-03-05
EA200970211A1 (ru) 2009-08-28
KR101495362B1 (ko) 2015-02-24
JP5315244B2 (ja) 2013-10-16
JP2010501519A (ja) 2010-01-21
AU2007287527B2 (en) 2013-01-31
AU2007287527A1 (en) 2008-02-28
EA017917B1 (ru) 2013-04-30
US20080058398A1 (en) 2008-03-06
MA30672B1 (fr) 2009-08-03
IL196976A0 (en) 2009-11-18
BRPI0716454A2 (pt) 2014-03-04
WO2008022994A1 (en) 2008-02-28
NO20090834L (no) 2009-03-19
ZA200900886B (en) 2011-05-25
GB0616574D0 (en) 2006-09-27
TW200825074A (en) 2008-06-16
CO6150139A2 (es) 2010-04-20

Similar Documents

Publication Publication Date Title
AR062471A1 (es) SESQUIHIDRATO CRISTALINO DEL TARTRATO DE 1-[2-FLUORO-4-(TRIFLUOROMETIL)-3-(3-{[4-METIL-5-(4-METIL-1, 3-OXAZOL-5-IL)-4H-1, 2, 4-TRIAZOL-3-IL]TIO}PROPIL)-3-AZABICICLO[3.1.0]HEXANO (1S, 5R) o (2R, 3R), SU USO PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR LA MODU
UY31431A1 (es) Inhibidor de la proteina activadora de la 5-lipoxigenasa (flap)
NO20084659L (no) Ko-krystall av C-glucosidderivat og L-prolin
CL2019001978A1 (es) Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo.
CL2009000161A1 (es) Compuestos derivados de 2,3,4,5-tetrahidro-1h-pirido[4,3-b]indol; composicion farmaceutica que los comprende; uso en el tratamiento de trastornos neurodegenerativos, cognitivos o psicoticos, enfermedad de alzheimer, entre otros; y un kit que contiene a los compuestos.
SV2011003912A (es) Moduladores de aril metil benzoquinazolinona alostericos positivos del receptor m1
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
GT200600163A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de la depresion
CL2008002864A1 (es) Compuestos derivados de 2-amino-quinolina, antagonistas del receptor de serotonina 5-ht 5a; procedimiento de preparacion;composicion farmaceutica; y uso de los compuestos en la prevencion o el tratamiento de depresion,trastornos de ansiedad,esquizofrenia,trastornos de panico,trastornos de memoria,demencia,entre otros.
CL2008002793A1 (es) Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
CL2009000662A1 (es) Compuestos derivados de 1,2,4-triazol trisustituidos, moduladores del receptor de acetilcolina nicotinicos; composicion farmaceutica; su proceso de preparacion; y uso para la prevencion o el tratamiento de trastornos psicoticos, trastornos o enfermedades de daño intelectual, o enfermedades o trastornos inflamatorios.
CL2008003822A1 (es) Compuestos derivados de n1-(2-tiazolil)-1,2-dicarboxamida pirrolidina; procedimiento de preparacion; composicion farmaceutica; combinacion farmaceutica; y uso para el tratamiento de enfermedades mejoradas por la inhibicion de la fosfatidilinositol-3-cinasa, como el cancer.
CL2011002697A1 (es) Compuestos derivados de 3-[4-(oxo-dihidropiridin)bencil]-1,3-oxazin-ona hidratados, inhibidores 11beta-hsd1; composicion farmaceutica que los comprende; y su uso en el tratamiento de la diabetes
CL2012003211A1 (es) Compuestos derivados de lactamas sustituidas con piperidinilo, moduladores de gpr119; proceso para preparar los compuestos; composicion farmaceutica que comprende a los compuestos; y uso de los compuestos en la preparacion de medicamentos para el tratamiento o prevencion de diabetes tipo 2, obesidad y condiciones relacionadas
DOP2012000025A (es) Derivados de piridina y pirazina como moduladores de cinasa de proteina
CL2011002706A1 (es) Compuestos derivados de 4-(1,3-oxazol-2-il)-1h-indazol; composicion farmaceutica que los comprende; y sus usos en el tratamiento de enfermedades tales como epoc, autoinmunes, asma, entre otras.
AR075729A1 (es) Derivados de benzofuranilo, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de la obesidad y/o diabetes.
CL2013000225A1 (es) Forma de dosificacion farmaceutica que contiene 6´-fluoro-(n-metil)-o-n,n,-dimetil)-4-fenil-4´,9´-dihidro-3´-h-espiro[ciclohexan-1,1´-pirano[3,4,b])indol]-4-amina para el tratamiento de dolor neuropatico.
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
CL2008000946A1 (es) Compuestos derivados de pirrolopirimidina, inhibidores de cianasa jak3; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de rechazo de transplantes, enfermedades autoinmun
EA200901373A1 (ru) Аминогетероциклические соединения
AR054786A1 (es) (6-fluor-benzol(1,3) dioxolil)-morfolin-4-il-metanomas, moduladoras del receptor cb1
PE20081736A1 (es) Compuestos triciclicos, composiciones, y procedimientos
PE20121084A1 (es) Forma de dosificacion farmaceutica para administracion oral de un inhibidor de la familia bcl-2

Legal Events

Date Code Title Description
FA Abandonment or withdrawal